Generics discuss fallout from major pharma patent cases
In-house counsel at global generic pharmaceutical companies point to Supernus, Novartis v Ezra and Helsinn as practically-important rulings for generics
Generic companies’ entire business relies on brands’ patents expiring, so anything that could delay pharmaceutical patents’ expiration is of acute interest to generics.
In its January 23 Supernus v Iancu decision, the Federal Circuit found that the USPTO’s patent term...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.